BIG BAM FOUNDATION INC
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : j****e@t******f.o*g
Mission Statement
BTTF is a grassroots organization committed to providing free breast, screening, diagnostic follow-up, treatment and education to low-income patients without access to health insurance in New York City. The costs of diagnostic follow-up services and treatments are extensive, often preventing low-income patients from obtaining the necessary treatment, or leaving them struggling with large medical debt. BTTF eliminates medical financial strains by offering the full range of breast care free of charge to uninsured patients. BTTF believes that all individuals should have access to breast cancer screening, diagnostic follow-up and treatment, regardless of age, race, financial status, and accessibility to health insurance.
About This Cause
Breast Treatment Task Force (BTTF) facilitates free breast screening, diagnostics, and treatment for NYC patients without health insurance. The average BTTF patient earns $30,000 annually, does not receive health benefits from her employer and cannot afford to pay $300 per month for an individual healthcare plan. BTTF facilitates ultrasounds, biopsies, MRIs, and other diagnostic procedures for uninsured patients above Medicaid eligibility that cannot otherwise receive access to services. Data/info is shared between BTTF and the referring CBO/FQHC (ScanVan, Charles B. Wang, Community Healthcare Network) and provider sites (RadNet, CP Advanced Imaging). Many women without a primary care physician self-refer themselves to the BTTF/Scan Van program. The BTTF provider network (30 private imaging centers in the five boroughs) is willing to donate or greatly reduce prices for otherwise unused capacity/appointments. BTTF 2019 Patient Demographics: 33% Asian (23% Chinese, 7% Korean, 2% Japanese, and 1% Filipino), 32% Latina/Hispanic, 22% African-American; 16% Caucasian.